Methods of preparing dendritic cells with flt3-ligand and antigen
US7150992B1 · kind B1 · utility
2Cited by
27References
5Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Oct 30, 2000 |
| Grant date | Dec 19, 2006 |
| Priority date | — |
| Expiry date | Oct 30, 2020 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12N2501/26
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Flt3-ligand can be used to generate large numbers of dendritic cells from hematopoietic progenitor and stem cells. Flt3-ligand can be used to augment immune responses in vivo, and expand dendritic cells ex vivo. Such dendritic cells can then be used to present tumor, viral or other antigens to naive T cells, can be useful as vaccine adjuvants. When flt3-L is used and/or administered in combination with other reactive agents, e.g. CD40 binding proteins and 4-1BBL or antibodies reactive with 4-1BB, the combination further enhances immune responses and the effectiveness of vaccine adjuvants.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.